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Simvastatin suppresses the 
DNA replication licensing factor 
MCM7 and inhibits the growth of 
tamoxifen-resistant breast cancer 
cells
Zheyong Liang1,2,*, Wenjie Li1,2,*, Jie Liu1,2, Juan Li1,2, Fang He1, Yina Jiang3, Lu Yang1, 
Pingping Li1,2, Bo Wang1,2, Yaochun Wang1,2, Yu Ren4, Jin Yang5, Zhijun Luo6, Cyrus Vaziri7 & 
Peijun Liu1,2
Acquired tamoxifen resistance (TamR) remains a major challenge in breast cancer endocrine 
therapy. The mechanism of acquiring tamoxifen resistance remains elusive, and no effective drugs 
are available. In this investigation, we determined that the expression of the DNA damage marker 
γH2AX is upregulated under minichromosome maintenance protein 7 (MCM7) knockdown in phospho 
Ser807/811-retinoblastoma protein (p-Rb) defect cells. In addition, the expression of p-Rb was lower 
in TamR cells than in parental cells, and the expression of γH2AX was significantly upregulated when 
MCM7 was knocked down in TamR cells. Simvastatin, an agent for hypercholesterolemia treatment, 
activated the MCM7/p-RB/γH2AX axis and induced DNA damage in TamR cells, especially when 
combined with tamoxifen. Finally, in vitro and in vivo experiments demonstrated that simvastatin 
combined with tamoxifen increased TamR cell apoptosis and inhibited xenograft growth. In conclusion, 
simvastatin may suppress TamR cell growth by inhibiting MCM7 and Rb and subsequently inducing DNA 
damage.
Adjuvant endocrine therapies can halve the recurrence rate of estrogen receptor (ER)-positive breast cancer. 
However, approximately one in three ER-positive patients relapse during or after endocrine therapy1,2. Despite 
numerous studies of new markers and mediators of therapeutic resistance, effective drugs remain lacking3. 
Therefore, a better understanding of the molecular mechanisms underlying endocrine therapy resistance and the 
identification of targets that can overcome this resistance are urgently needed.
Tamoxifen, a selective estrogen receptor (ER) modulator, is most frequently used as an adjuvant endocrine 
therapy for women with ER-positive breast cancer4,5. Tamoxifen resistance in ER-positive breast cancer has 
been recently demonstrated to be associated with the activation of retinoblastoma protein (Rb). Recently, Bosco 
et al.6 reported that Rb-deficient cells partially bypass the cell-cycle blockade elicited by anti-estrogen therapy. 
Additionally, Lehn et al.7 showed that the functional status of Rb appears to be related to the patient’s response to 
tamoxifen treatment and that the loss of RB function is associated with approximately 40% of ER-negative cancer 
as opposed to approximately 5% of ER-positive cases. In fact, Rb deficiency is reported in approximately 20–35% 
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of breast cancers8,9. Rb is a well-known G1/S checkpoint control protein10,11, but the association of Rb defect with 
the potential dysregulated DNA replication in tamoxifen-resistant breast cancer cells has not been established.
Minichromosome maintenance protein 7 (MCM7) is part of the MCM complex (MCM2–7) hexamer and 
a DNA replication licensing factor that plays a central role in eukaryotic DNA replication12,13. The MCM com-
plex binds and translocates along the DNA, resulting in the unwinding of the DNA strand14. The suppression of 
MCMs increases the frequency of chromosome breaks and chromosome gaps in cells under replication stress15. 
Once the MCM complex is destroyed by downregulating any one of its subunits, cells will undergo limited repli-
cation and become hypersensitive to DNA replication stresses, easily causing DNA damage and further inhibiting 
cell growth via activating the checkpoint signals15. Therefore, we hypothesized that under the dysregulated DNA 
replication conditions caused by the Rb defect in tamoxifen-resistant cells, the additional destruction of the MCM 
complex may cause severe DNA damage.
We previously showed that simvastatin, an agent for the treatment of hypercholesterolemia16,17, reduces the 
expression of MCM7 and causes a significant upregulation of γ H2AX expression; therefore, we proposed that 
simvastatin may cause DNA damage in tamoxifen-resistant breast cancer cells in which p-Rb expression is low 
via downregulation of MCM7.
In this study, we investigated the unconventional effects of the conventional drug simvastatin on breast cancer 
with tamoxifen resistance. We observed that simvastatin downregulated the expression of MCM7 and caused 
DNA damage in tamoxifen-resistant cells when combined with tamoxifen treatment. Notably, our results demon-
strate for the first time that simvastatin, combined with tamoxifen, induces the apoptosis of tamoxifen-resistant 
cells and inhibits their growth both in vitro and in vivo.
Results
Characteristics of tamoxifen-resistant cells. Initially, we assessed the drug resistance of the TamR cell 
lines using MTT (Fig. S1A). Based on the results of the MTT assay, the IC50 in each cell line was as follows: 
MCF-7 4.378 μ M; MCF-7 TamR 13.100 μ M; T47D 5.120 μ M and T47D TamR 11.146 μ M. In addition, the tamox-
ifen resistance factor (RF) of each cell was calculated as follows: MCF-7 TamR 2.99 and T47D TamR 2.18. The 
TamR cells grew more slowly than the WT cells (Fig. S1B), and this difference was confirmed by cell-cycle analysis 
(Fig. S1C and D). Furthermore, we investigated markers of breast cancer stem cells in TamR and WT cells. Both 
MCF7 TamR and T47D TamR cells had a larger population of CD24-CD44 + cells and a smaller population of 
ALDH high-activity cells than the corresponding WT cells (Fig. S1E to H). These results indicate that our TamR 
cell line models share some characteristics of mesenchymal-like human breast cancer stem cells (CSCs)18.
MCM7 knockdown increases γH2AX expression in tamoxifen-resistant breast cancer cells 
under an Rb-defective condition. We showed that MCM7 knockdown induces higher γ H2AX expres-
sion in SaOS2 cells (Rb inactivated) than in U2OS cells (Rb permanently activated). Similar effects have been 
observed in other cell lines, such as SiHa (Rb inactivated) and C33A (Rb normally activated) (unpublished data). 
In this study, MCM7 was knocked down with two different siRNAs, and the Rb signal was inactivated by HPV E7 
adenovirus (Ad E7)19. As expected, γ H2AX was upregulated in the Rb/MCM7 double-defective MCF7 and T47D 
cells (Fig. 1A to C and Fig. S2A to C).
Recently, Lehn et al. demonstrated that Rb inactivity is an important characteristic of tamoxifen-resistant 
breast cancer in the clinic7. This finding inspired us to examine whether the Rb signal was also inactivated in our 
cell line models and whether MCM7 downregulation in TamR cells induces γ H2AX upregulation. Western blot 
analysis showed that p-Rb expression was lower in MCF7 TamR and T47D TamR cells than that in their corre-
sponding WT cells (Fig. 1D). Next, we knocked down MCM7 in MCF7 TamR cells and T47D TamR cells using 
two different siRNAs. Interestingly, γ H2AX expression was also upregulated under MCM7 knockdown (Fig. 1E).
Simvastatin combined with tamoxifen upregulates γH2AX and induces DNA damage in 
tamoxifen-resistant breast cancer cells. If downregulating MCM7 induces the upregulation of γ H2AX 
in tamoxifen-resistant cells, drugs that cause MCM7 downregulation may induce DNA double-stranded breaks 
in tamoxifen-resistant cells. Previous studies by our group and other researchers20 have demonstrated that statins 
reduce the expression of MCM7; therefore, we investigated whether simvastatin also affects tamoxifen-resistant 
cells.
We observed that the expression of MCM7 was downregulated after TamR cells were treated with simvastatin 
at a dose of 20 μ M for 24 h (Fig. 2A). After treatment with either simvastatin (20 μ M) alone or in combination 
with tamoxifen (5 μ M) for 24 h, the expression of MCM7 was downregulated, and the expression of γ H2AX was 
upregulated in wild-type MCF7 and T47D cells (Fig. 2B). Notably, western blot analysis showed that the expres-
sion of MCM7 was downregulated and that the expression of γ H2AX was significantly increased in TamR cells 
after treatment with simvastatin combined with tamoxifen for 24 h (Fig. 2C). Immunofluorescence staining also 
showed that γ H2AX foci formed in the nucleus after treatment with simvastatin combined with tamoxifen at both 
24 h (Fig. 2D) and 72 h (Fig. S3A and B).
Alkaline comet assays were performed to determine whether DNA damage occurred following treatment. 
DNA damage was more severe in MCF7 TamR cells than in control cells after treatment with simvastatin com-
bined with tamoxifen for 24 h (Fig. 2E). We also estimated the extent of chromosomal damage after treatment in 
TamR cells by chromosome spread analyses. Colchicine was added to drive the cells into mitosis, and chromo-
some spreads were scored for signs of instability, such as breaks, gaps, and aberrant rearrangements (triradial or 
quadriradial chromosomes) (Fig. 2F). Furthermore, western blot analysis showed that the checkpoint proteins 
p-ATM, p-ATR, p-Chk1, and p-Chk2 were upregulated after treatment with simvastatin combined with tamox-
ifen for 24 h (Fig. 3G).
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Figure 1. Downregulation of MCM7 induces γH2AX over-expression in tamoxifen-resistant breast 
cancer cells under the condition of an Rb defect. (A,B) Both MCF7 and T47D cells were infected with HPV 
E7 adenovirus (Ad E7) or control adenovirus (Ad CON) for 24 h and were then transfected with MCM7 
siRNA or non-target siRNA (siNT). Forty-eight hours after transfection, the cells were lysed, and western 
blot was performed. (C) The MCF7 and T47D cells were infected with HPV E7 adenovirus (Ad E7) or control 
adenovirus vector (Ad CON) for 24 h and were then transfected with MCM7 siRNA. Forty-eight hours after 
transfection, the cells were fixed, and γ H2AX was stained by immunofluorescence. The bars represent 50 μ m. 
(D) The expression of p-RB, RB and MCF7 in wild-type cells and tamoxifen-resistant cells. (E) MCF7 TamR 
and T47D TamR cells were transfected with MCM7 siRNA or non-target siRNA (siNT). Forty-eight hours after 
transfection, the cells were lysed, and a western blot was performed.
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Figure 2. Simvastatin combined with tamoxifen upregulates γH2AX and induces DNA damage in tamoxifen-
resistant breast cancer cells. (A) MCF7 and T47D cells were cultured at different doses (0 μ M, 10 μ M and 20 μ M) 
of simvastatin. After treatment for 24 h, the cells were lysed, and a western blot was performed. (B) Four groups 
of MCF7 TamR and T47D TamR cells were cultured with a control solvent, 4-OH-tamoxifen (5 μ M), simvastatin 
(20 μ M), or 4-OH-tamoxifen (5 μ M) plus simvastatin (20 μ M). After treatment for 24 h, the cells were lysed, and 
a western blot was performed. (C) Four groups of MCF7 TamR and T47D TamR cells were cultured as described 
above. After treatment for 24 h, the cells were lysed, and a western blot was performed. (D) Four groups of MCF7 
TamR and T47D TamR cells were cultured as described above. After treatment for 24 h, the cells were fixed, and 
immunofluorescence was performed. The images were obtained by fluorescence confocal microscopy; the bars 
represent 10 μ m. (E) Four groups of MCF7 TamR cells were cultured as described above. After treatment for 
24 h, comet assays were performed under alkaline conditions. Images were obtained by fluorescence confocal 
microscopy; the bar represents 100 μ m. (H) Quantitative analysis of the DNA content in the comet tail relative to 
the total DNA content in each group of cells. Fifty cells were scored per group. *p < 0.05. (F) Four groups of MCF7 
TamR and T47D TamR cells were cultured as described above. After treatment for 24 h, chromosome fragility 
analyses were performed, and representative images are shown. The chromosome gaps and breaks (indicated as 
arrows) were scored. Two metaphases were analyzed for each cell group. (G) Four groups of MCF7 TamR and 
T47D TamR cells were cultured as described above. After treatment for 24 h, the cells were lysed, and a western blot 
was performed.
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Simvastatin combined with tamoxifen inhibits the growth of tamoxifen-resistant breast cancer 
cells. Because simvastatin induced DNA damage in TamR cells, we examined whether simvastatin inhibits the 
growth of TamR cells. Cell viability was assessed by MTT assay at 24 h, 48 h and 72 h after treatment with different 
concentrations of simvastatin. Simvastatin had little effect on either MCF7 TamR or T47D TamR cell growth at a 
low concentration (5 μ M) but inhibited cell growth significantly at a high concentration (10 μ M). In addition, the 
Figure 3. Simvastatin combined with tamoxifen inhibits the growth of tamoxifen-resistant breast cancer 
cells. (A,B) Both MCF7 TamR and T47D TamR cells were treated with simvastatin at doses ranging from 5 μ M  
to 40 μ M for 72 h; cell viability was measured by an MTT assay at 0 h, 24 h, 48 h and 72 h following treatment. 
(C,D) Four groups of MCF7 TamR or T47D TamR cells were cultured with solvent as a control, 4-OH-
tamoxifen (5 μ M), simvastatin (20 μ M), or 4-OH-tamoxifen (5 μ M) plus simvastatin (20 μ M). After treatment 
for 24 h (C) or 72 h (D), cell viability was measured by an MTT assay. (E,F,G) Four groups of MCF7 TamR and 
T47D TamR cells were cultured as described above. After treatment for 24 h, the cell cycle was evaluated by flow 
cytometry in each group. (H) Four groups of MCF7 TamR and T47D TamR cells were cultured as described 
above. After treatment for 24 h, the cells were lysed, and a western blot was performed. n = 3, *p < 0.05, 
#p < 0.01, **p < 0.01
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inhibitory effects of simvastatin were time- and concentration-dependent (Fig. 3A and B). Next, we observed that 
cell viability was inhibited when the cells were treated with simvastatin (20 μ M) combined with tamoxifen (5 μ M) 
for 24 h, and the growth of the cells was also inhibited after treatment with simvastatin alone for 72 h (Fig. 3C and D). 
Furthermore, cell-cycle analysis revealed that MCF7 TamR cells accumulated in G1 phase when treated with 
simvastatin alone or in combination with tamoxifen, but this accumulation was less notable in T47D TamR cells 
(Fig. 3E to G). Notably, western blot analysis indicated that the expression of p-Rb was downregulated and the 
expression of p27 was upregulated in TamR cells after treatment with simvastatin combined with tamoxifen for 
24 h. However, the expression of PCNA, cyclin D1 and p21 did not exhibit significant changes (Fig. 3H).
Simvastatin combined with tamoxifen induces apoptosis in tamoxifen-resistant breast 
cancer cells. Apoptosis assays were performed to investigate whether simvastatin induces apoptosis in 
tamoxifen-resistant cells. The number of apoptotic cells increased in MCF7 TamR or T47D TamR cells after treat-
ment with simvastatin combined with tamoxifen for 24 h or 72 h (Fig. 4A to D). The number of apoptotic cells 
also increased in MCF7 TamR or T47D TamR cells after treatment with simvastatin alone for 72 h. As expected, 
western blot analysis revealed that cleaved caspase 3 and cleaved caspase 9 were upregulated in MCF7 TamR and 
Figure 4. Simvastatin combined with tamoxifen induces apoptosis of tamoxifen-resistant breast cancer 
cells. (A,B,C,D) Four groups of MCF7 TamR and T47D TamR cells were cultured with solvent as a control, 
4-OH-tamoxifen (5 μ M), simvastatin (20 μ M), or 4-OH-tamoxifen (5 μ M) plus simvastatin (20 μ M). After 
treatment for 24 h (C) or 72 h (D), the cells were digested and incubated with PE Annexin V and 7-AAD, and 
apoptotic cells were detected by flow cytometry. (E) Four groups of MCF7 TamR and T47D TamR cells were 
cultured as described above. After treatment for 24 h, the cells were lysed, and a western blot was performed. 
n = 3, *p < 0.05, **p < 0.01 and ****p < 0.0001.
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T47D TamR cells after treatment with simvastatin combined with tamoxifen for 24 h, whereas Bcl2 exhibited 
little change following either treatment (Fig. 4E). We also observed that cleaved caspase 3 and cleaved caspase 9 
were upregulated in MCF7 TamR cells after treatment with simvastatin alone for 72 h (Fig. S4). However, caspase, 
PARP and Bcl2 proteins were significantly degraded in T47D TamR cells after treatment with simvastatin alone 
or combined with tamoxifen for 72 h (Fig. S4). Thus, simvastatin combined with tamoxifen induces apoptosis in 
TamR cells.
Simvastatin combined with tamoxifen inhibits the growth of tamoxifen-resistant breast can-
cer cells in vivo. Xenograft tumor models were established in SCID/Beige mice using wild-type MCF7 cells 
and tamoxifen-resistant MCF7 cells to further investigate the in vivo effects of simvastatin. First, we assessed the 
tumorgenicity of these two cell lines. Approximately 2.5 × 106 wild-type or tamoxifen-resistant MCF7 cells were 
injected into the fat pads of six-week-old SCID/Beige mice. Consistent with the findings of the in vitro experi-
ment, the tumors formed by MCF7 TamR cells grew more slowly than those formed by wild-type MCF7 cells 
(Fig. 5A to C). Next, seven days after the injection, when the xenograft tumors were palpable, the mice injected 
with MCF7 TamR cells were randomly allocated to either tamoxifen (5 mg/kg) alone, simvastatin (30 mg/kg) 
alone or tamoxifen (5 mg/kg) combined with simvastatin (30 mg/kg) by gavage daily. The tumor volumes 
were measured every 3 days. After three weeks, the tumor size and weight decreased remarkably in the mice 
treated with simvastatin combined with tamoxifen compared with the mice in the placebo group (Fig. 5D to F). 
Furthermore, immunochemistry staining revealed lower MCM7 expression in the xenograft tumors in the sim-
vastatin combined with tamoxifen group (Fig. 5G). Taken together, these data support the hypothesis that sim-
vastatin suppresses TamR cell growth and inhibits MCM7 expression.
Discussion
In the present study, we initially established two tamoxifen-resistant cell lines and tested the effects of sim-
vastatin on these cells. Our data indicated that simvastatin upregulated γ H2AX and induced DNA damage in 
tamoxifen-resistant cells. In addition, simvastatin inhibited the growth of tamoxifen-resistant cells and induced 
apoptosis in these cells when administered in combination with tamoxifen. Importantly, the expression of MCM7 
and Rb was downregulated under simvastatin treatment; this downregulation may be the mechanism underlying 
the growth-inhibiting effects of simvastatin. The growth-inhibiting effect of simvastatin on tamoxifen-resistant 
cells was also confirmed in our in vivo studies. Taken together, these results suggest that simvastatin may be a 
potential treatment for tamoxifen-resistant breast cancer patients.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a 
rate-limiting enzyme that converts HMG-CoA to mevalonate in the synthesis of cholesterol16,17. In addition to 
their original role in lowering serum cholesterol levels, accumulating evidence suggests that statins may inhibit 
carcinogenesis21–27 and that the anticancer effect of statins can be potentially exploited for cancer therapy28,29. 
Retrospective studies have concluded that the long-term use of statins reduces the risk of colorectal cancers30. 
However, the anti-tumor targets of simvastatin remain elusive. In our study, we investigated the effects of simvas-
tatin on tamoxifen-resistant breast cancer cells and determined that MCM7 downregulation may contribute to 
simvastatin’s effects.
The MCM complex, as an important DNA replication initiation factor12, is a key regulator of the cell cycle. 
The MCM complex participates in the formation of the pre-replication complex, which assembles at replication 
origins during the early G1 phase31–34 and is responsible for the correct licensing of DNA. Ibarra and his colleges15 
demonstrated that knockdown any one of the MCM complex subunits (MCM2-7) will lead to dysfunction of the 
whole complex and reduce the backup capacity of DNA licensing, which then leads to abnormal replication of 
DNA during S phase and activates the DNA damage response (DDR) to stop the cell cycle. In fact, downregulat-
ing MCM7 alone also activates DDR by regulating Rad1735,36. Our data showed that simvastatin downregulated 
MCM7 in TamR cells, which in turn induced the upregulation of γ H2AX. These observations imply that MCM7 
contributes to the growth-inhibiting effects of simvastatin. MCM7 may not be the only target of simvastatin. 
Archana Gopalan et al.37 found the combination of that simvastatin with γ -tocotrienols reduced the number 
of stem-like cells in tamoxifen-resistant breast cancer cells. We observed that simvastatin also reduced the RB 
signals and influenced the expression of cyclinD1 and p27 in TamR cells. Our in vivo experiment shown that sim-
vastatin alone reduced the growth of tumor significantly but the effect of tamoxifen combined with simvastatin 
does not look different from the effect of simvastatin alone. It indicated that simvastatin may didn’t restore the 
tamoxifen sensitivity of the cells in vivo. Other mechanism that independent of the hormone receptor pathway 
may contribute to the tumor growth inhibition effects of simvastatin. Based on our results, we assume that under 
the uncontrolled cell-cycle progression caused by the Rb defect in TamR cells, the additional inactivation of the 
MCM complex reduces the backup capacity of DNA licensing, which then causes lethal DNA damage and further 
contributes to apoptosis in tamoxifen-resistant cells. In fact, an Rb signal defect is observed in approximately 
20–35% of breast cancers8,9, and thus whether simvastatin also inhibits other Rb-defect tumor cells merits further 
investigation.
In summary, we established two tamoxifen-resistant cell lines and determined that downregulating MCM7 in 
TamR cells induced the upregulation of γ H2AX. We also observed that simvastatin downregulated MCM7 and 
induced DNA damage in TamR breast cancer cells. Furthermore, simvastatin inhibited the growth and induced 
apoptosis in TamR cells. Our data indicate that the growth-inhibitory effects of simvastatin are probably achieved 
by downregulating MCM7 when defective Rb signals are present. This study provides support for the further 
evaluation of simvastatin as a new strategy for the treatment of patients with tamoxifen-resistant breast cancer.
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Figure 5. Simvastatin combined with tamoxifen inhibits the growth of tamoxifen-resistant breast cancer 
cells in vivo. Xenograft tumors were formed by injecting 2.5 × 106 MCF7 or MCF7 TamR cells into the fat 
pads of SCID/Beige mice. (A) Tumors in the non-treated group are shown. (B,C) The xenograft tumors that 
formed from the MCF7 cells were significantly larger in size (B) and weight (C) than the tumors that formed 
from MCF7 TamR cells. (D,E,F) Six days after injection, the SCID/Beige mice were gavaged daily with placebo 
(CON) and tamoxifen (5 mg/kg) alone (TAM), simvastatin (30 mg/kg) alone (SVA) or tamoxifen (5 mg/kg) 
combined with simvastatin(30 mg/kg) (TAM + SVA) for 3 weeks. The xenograft size (D,E) and weight (F) are 
shown. (G) Immunochemical staining was performed to assess the expression of MCM7 and RB in the CON, 
TAM, SVA and TAM + SVA groups; the bars represent 75 μ m. n = 8, *p < 0.05, **p < 0.01 and ***p < 0.001.
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Methods
Cell culture and treatments. Human MCF7 and T47D breast carcinoma cells, which were purchased from 
Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), were rou-
tinely grown in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, USA) containing 5% fetal bovine serum 
(FBS; Gibco, USA). The cell lines were authenticated by a short-tandem repeat analysis by the cell bank. The 
tamoxifen-resistant sublines (MCF7 TamR or T47D TamR) were derived from MCF-7 or T47D by continuous 
exposure to tamoxifen as previously described38. In brief, a single-cell suspension of MCF7 or T47D cells was 
incubated at a high density and then cultured for 30 days in DMEM (5% FCS) supplemented with 1 μ M 4-hydrox-
ytamoxifen (Sigma-Aldrich, USA). Massive cell death occurred after 5–10 days of drug exposure, and colonies 
emerged after 20 days of drug exposure. The developed colonies (> 3 mm diameter) were examined separately, 
and each colony was isolated and transferred to a well of a 96-well cell-culture plate. After several rounds of drug 
selection, the TamR monoclonal sublines were established and maintained in phenol-free DMEM containing 5% 
charcoal-dextran stripped FBS supplemented with 4-hydroxytamoxifen (1 μ M in ethanol). Before each exper-
iment, the cells were transferred to phenol-free DMEM containing 5% charcoal-dextran stripped FBS, except 
where noted.
Cell viability assay. The cells were seeded in 96-well plates at 5 × 103 cells/well. On day 2, the cells were 
treated with different concentrations of TAM or SVA for the time period indicated. Vehicle (0.1% ethanol or 
DMSO) was used as a control. At the end of the treatment, 20 μ l of 5 mg/ml MTT was added to the medium 
and incubated for 4 hours at 37 °C. After removing the medium, 150 μ l of MTT solvent (DMSO) was added to 
each well for 15 minutes, and the optical density (OD) values were read using a microplate reader (PerkinElmer, 
Waltham, MA, USA) (λ = 490 nm). Each experiment was repeated three times. All OD values were normalized 
by converting them to a percentage of the mean control value.
Analysis of the cell cycle and apoptosis. After incubation, the cells were harvested, fixed in cold 70% eth-
anol, and stored at − 20 °C for at least 20 min. After a PBS wash, the cell pellets were resuspended in 50 g/ml propid-
ium iodide (PI) containing 20 g/ml RNase for 30 min. Then, the cell DNA content was measured by propidium 
iodide staining and flow cytometry (FACSort, Becton-Dickinson) using the Cell Quest software program. At least 
10,000 cells were counted in each sample. The forward and side scatters were gated to exclude contributions from cell 
debris. Cell apoptosis was assayed using a PE Annexin V Apoptosis Detection Kit (BD Biosciences; USA).
siRNA and adenovirus. One hundred picomoles of siRNA and 5 μ l of Lipofectamine™ 2000 (Invitrogen, 
Life Technologies, Shanghai, China) were each diluted separately in 245 μ l of opti-MEM medium (Gibco), respec-
tively. The diluted siRNA and Lipofectamine™ 2000 reagents were mixed and incubated at room temperature 
(RT) for 15 minutes. The siRNA-lipid complex was added to cells that had been grown to 70–80% confluence 
in six-well plates, and the cells were incubated at 37 °C in a 5% CO2 incubator. The sequences of the sense and 
antisense primers were as follows: MCM7 siRNA#1 sense: 5′ -AUCGGAUUGUGAAGAUGAATT-3′ ; antisense: 
5′ -UUCAUCUUCACAAUCCGAUTT-3′ and MCM7 siRNA#2 sense: 5′ -GCUCCAGAUUCAUCAAAUUTT-3′ ; 
antisense: 5 ′  -AAUUUGAUGAAUCUGGAGCTT-3 ′   and negative control (NC) siRNA sense: 
5′ -UAGCGACUAAACACAUCAATT-3′ ; antisense: 5′ -UUGAUGUGUUUAGUCGCUATT-3′ . The HPV E7 
adenovirus and an ‘empty’ control adenovirus vector were packaged, and the cells were infected as previous 
described19.
Western blot assay. The cells were lysed with RIPA buffer supplemented with protease inhibitors (Roche, 
NJ, USA) and phosphatase inhibitors. The protein lysates were separated by 10% SDS-PAGE and transferred to 
PVDF membranes (Bio-Rad, CA, USA), and the membranes were incubated with the indicated antibodies. The 
PARP, caspase-3, caspase-9, PCNA, γ H2AX, p-RB, p-ATM, p-ATR, p-Chk1 and p-Chk2 primary antibodies 
were obtained from Cell Signaling Technology, USA. The MCM7, p21, p27 and Bcl2 primary antibodies were 
obtained from Santa Cruz, USA. The Rb, cyclin D1, GADPH and β -actin primary antibodies were obtained from 
Proteintech, China.
Immunofluorescence. The cells were cultured on chamber slides in DMEM and were fixed with a 4% para-
formaldehyde solution for 15 min at RT after being treated for 24 h or 72 h. The cells were washed three times with 
PBS and then permeabilized with 0.2% Triton X-100 for 10 min. The slides were blocked with 5% BSA and 10% 
horse serum in PBST for 1 h at RT and were then incubated with antibodies against γ H2AX (1:200) (Cell Signal 
Technology, #9718P; USA) at 4 °C overnight. After rinsing with PBST three times, the cells were incubated with 
an Alexa Fluor 488 secondary antibody (Invitrogen #A11008; USA) (1:200) for 45 min at RT. Then, the cells were 
washed twice and were stained with 5 μ g/ml DAPI, followed by imaging using a confocal microscope (Leica SP5II).
Comet Assay. Alkaline comet assays were performed on MCF7 TamR cells using a Single Cell Gel 
Electrophoresis Assay Kit (Trevigen, Inc., USA) according to the manufacturer’s instructions. One hundred 
cells were spotted onto each sample area, and 50 cells from each group were analyzed and quantified using the 
CASP1.2.3 beta1 software (Krzysztof Konca, Comet Assay Software Project Lab, http://caspla.com).
Chromosome spread analyses. The cells were treated with 0.5 g/ml of colchicine for 5 h at 37 °C before 
collection. To prepare the metaphase spreads, the cells were resuspended in 75 mM KCl, incubated for 15 min at 
37 °C, centrifuged, and resuspended in fixation solution (3:1 vol/vol methanol/acetic acid). One hundred micro-
liters of the cell suspension was dropped onto pre-cleaned microscope slides and dried overnight. The metaphase 
chromosomes were visualized by Giemsa staining.
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Animals, xenotransplantation and treatments. All animal experiment protocols were approved by the 
Institutional Animal Care and Use Committee of the First Affiliated Hospital of Xi’an Jiaotong University. The meth-
ods were conducted in accordance with the approved guidelines. A total of 2.5 × 106 cells resuspended in 200 ml of 
PBS was injected subcutaneously into the fat pads of six-week-old female SCID/Beige mice (Centre of Laboratory 
Animals, The Medical College of Xi’an Jiaotong University, Xi’an, China). Tamoxifen (5 mg/kg in peanut oil) was 
administered daily by gavage as previously described39. Simvastatin (30 mg/kg in distilled water) was administered 
daily by gavage. Tumor volume was calculated using the following formula: (long axis × short axis2)/2.
Immunohistochemical staining. Immunohistochemistry was performed on paraformaldehyde-fixed par-
affin sections. The paraffin-embedded samples were cut into 4-μ m-thick sections, which were baked at 60 °C for at 
least 6 hours. The paraffin sections were then deparaffinized in xylene and rehydrated in graded ethanol. Antigen 
retrieval was performed by treatment with sodium citrate buffer for 2 minutes in a pressure cooker. After antigen 
retrieval, endogenous peroxidase activity was quenched in 3% hydrogen peroxide for 10 min, followed by block-
ing with goat plasma at 37 °C for 30 minutes and incubation with the MCM7 antibody (1:100, Santa Cruz; USA) 
or Rb antibody (1:100, Proteintech; China) at 4 °C overnight. A biotinylated secondary antibody (ZSGB-Bio, 
Beijing, China) was used to detect the primary antibody. Then, the sections were incubated with diaminoben-
zidine before counterstaining with hematoxylin. Finally, the sections were dehydrated in graded ethanol and 
transparentized in xylene.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 6.00 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad). The values are expressed as the mean ± SD. 
Comparisons between two groups were performed using an unpaired Student’s t-test. Two-way ANOVA followed 
by Dunnett’s multiple comparisons test was used for multiple comparisons. All statistical tests were two-sided. 
p < 0.05 was considered an indicator of statistical significance.
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